Theranos' Correction Plan For Lab Not Enough To Stop CMS Threat
This article was originally published in Clinica
Beleaguered laboratory firm Theranos Inc. said late last month that it submitted a correction plan to the Center for Medicare and Medicaid Services to remedy the uncorrected testing deficiencies cited from an inspection by the Medicare agency. But the firm's actions so far have not been enough to stop CMS from proposing sanctions on the company in a March 18 letter, including the potential of barring its California location from operating as a clinical laboratory.
Register for our free email digests: